openPR Logo
Press release

Chemotherapy-induced Nausea and Vomiting (CINV) Market Expected to Reach $2,659 Million, Globally, By 2022

01-11-2017 11:48 AM CET | Health & Medicine

Press release from: Allied Market LLP

Chemotherapy-induced Nausea and Vomiting (CINV) Market

Chemotherapy-induced Nausea and Vomiting (CINV) Market report, published by Allied Market Research, forecasts that the global market is expected to garner $2,659 million by 2022, growing at a CAGR of 7.1% during 2016-2022.

Access Full Summary At: https://www.alliedmarketresearch.com/cinv-market

Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016, approximately 1.6 million new cases of cancer will be diagnosed with breast, lung, and bronchus cancer. It is observed that approximately 35% of patients experienced nausea within 24 hours of chemotherapy, while 54% suffered from nausea and 34% experienced vomiting after 24 hours.
Growth in number of patients undergoing chemotherapy drugs treatment and introduction of new drug delivery methods to improve patient compliance are the major factors that significantly impact the growth of the CINV market. At present, pharmaceutical companies are increasingly investing in the R&D of CINV drugs to offer better chemotherapy drugs and increase their market share.
According to Sriram Radhakrishnan (Team Lead, Healthcare Research) at Allied Market Research, The needle free, painless, and cost-effective transdermal delivery system is expected to witness increase in demand in global CINV market.

KEY FINDINGS OF THE CINV MARKET STUDY

The Aloxi segment generated highest revenue in the global market in 2015, accounting for over half of the total market.
The Netupitant-Palonosetron FDC segment is the fastest growing segment at a CAGR of 10.8%.

The North American market has witnessed a significant growth in the recent years. Presently, it is the largest regional market for CINV drugs and an its market share is anticipated by 2022. Asia-Pacific is the fastest growing market due to increase in number of cancer population, high incidences of gastroenteritis and other diseases that lead to nausea and vomiting. This region boosts up the demand for antiemetic drug due to growth in demand for CINV drugs and is expected to fuel the market growth in this region.
Partnership and collaboration is the key strategy adopted by companies to strengthen their position in the market. The key major players in the global chemotherapy-induced nausea and vomiting drugs are GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc.

Allied Market Research is a global market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pune ( India )
Office No.102D & E,2nd Floor,
A-3 Building E space IT park ,
Pune Nagar Road,
Pune 411014.
Tel: +91 20 66346060
help@alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chemotherapy-induced Nausea and Vomiting (CINV) Market Expected to Reach $2,659 Million, Globally, By 2022 here

News-ID: 409690 • Views: 346

More Releases from Allied Market LLP

Polyethylene Films Market 2023 Analysis of Key Trends and Drivers Shaping Future …
According to the report published by Allied Market Research, the global Polyethylene Films Market garnered $73.50 billion in 2017 and is expected to reach $90.91 billion by 2022, registering a CAGR of 3.6% from 2017 to 2023. The report has been prepared based on an in-depth market analysis with inputs from industry experts. It includes a study of the market size and share, market dynamics, market classification, and its growth prospects
Butadiene Market Statistics 2027: Major Factors that can Increase the Global Dem …
Allied Market Research published a new report, titled, "Butadiene Market." The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five Forces analysis, and competitive landscape. This study is a helpful source of information for market players, investors, VPs, stakeholders, and new entrants to gain thorough understanding of the industry and determine steps to be taken to gain competitive advantage. The report offers key drivers that
Traction Motor Market Analysis, Key Players, Challenges, Segmentation and Foreca …
Allied Market Research published a report titled, “Traction Motor Market by Application (Railways, Electric Vehicle and Industrial Vehicles), Type (DC Traction Motor, AC Traction Motor and Synchronous Motor) and Power Rating (Less than 200 kW, 200-400 kW and More than 400 kW): Global Opportunity Analysis and Industry Forecast, 2020–2027.”According to the report, the global traction motor industry was estimated at $10.78 billion in 2019, and is expected to hit $30.06
Flip Chip Market registering a CAGR of 9%; Powered by High Demand from IoT Devic …
Flip Chip Market Report by Allied Market Research, forecasts that the global market is expected to garner $46 billion by 2022, registering a CAGR of 9% during the period 2016-2022. Asia-Pacific dominated the global flip chip market and contributed over half of the market share owing to thriving market for semiconductors and electronic devices. The exclusive advantages of flip chip such as less space consumption, better efficiency, more I/O options as

All 5 Releases


More Releases for CINV

CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to I …
CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the
CINV Existing and Pipeline Drugs Market is Expected to Surpass US$1.88 bn by 202 …
The global chemotherapy induced nausea and vomiting (CINV) drugs market is dominated by players such as Helsinn Holding S. A., Merck & Co. Inc., Tesaro Inc., and Heron Therapeutics, says Transparency Market Research (TMR) in a new study. Helsinn Holding S.A. along with its commercial partner Eisai Co. Ltd. led the overall CINV drugs market by revenue in 2013. The large companies are entering into a number of strategic alliances
Chemotherapy Induced Nausea and Vomiting CINV Drugs Market Excellent Growth Scop …
A new research study from HTF MI with title Global Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs Market Size, Status and Forecast 2025 provides an in-depth assessment of the Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. The research study provides forecasts for Chemotherapy Induced Nausea and Vomiting ?CINV? Drugs investments till 2022. Access
CINV Existing and Pipeline Drugs Market will Surpass US$1.88 bn by 2020
The global chemotherapy induced nausea and vomiting (CINV) drugs market is dominated by players such as Helsinn Holding S. A., Merck & Co. Inc., Tesaro Inc., and Heron Therapeutics, says Transparency Market Research (TMR) in a new study. Helsinn Holding S.A. along with its commercial partner Eisai Co. Ltd. led the overall CINV drugs market by revenue in 2013. The large companies are entering into a number of strategic alliances
CINV Existing and Pipeline Drugs Market Projected to Reach US$1.88 bn by 2020
The global chemotherapy induced nausea and vomiting (CINV) drugs market is dominated by players such as Helsinn Holding S. A., Merck & Co. Inc., Tesaro Inc., and Heron Therapeutics, says Transparency Market Research (TMR) in a new study. Helsinn Holding S.A. along with its commercial partner Eisai Co. Ltd. led the overall CINV drugs market by revenue in 2013. The large companies are entering into a number of strategic alliances
Chemotherapy-induced Nausea and Vomiting (CINV) Market Grow $2, 659 Million By 2 …
Nausea and vomiting is one of the common side effects of chemotherapy in the cancer patients. Because of such side effects, the patient population either refuse or deferment the therapeutic chemotherapy treatment for cancer. For More Info, Get Sample: http://bit.ly/2zVmL28 The global Chemotherapy-induced Nausea and Vomiting market was valued at $1,663 million in 2015 and is estimated to reach $2, 659 million by 2022, registering a CAGR of 7.1%